Full Press Release Details
| Tenon Medical, Inc. Announces Adjournment of Special Meeting of Stockholders | |
| Tenon Medical, Inc. |
Meeting adjourned to Monday, January
8, 2024 at 1:30pm Pacific Time
LOS GATOS, CA / ACCESSWIRE / December 22,
2023 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients
suffering with certain sacroiliac joint disorders, today announced that the December 21, 2023 Special Meeting of Stockholders was adjourned
to January 8, 2024 at 1:30pm Pacific Time to provide additional time to obtain stockholders' votes on Proposal 2, approval of an amendment
of the Certificate of Incorporation. For additional information, please refer to the proxy statement previously filed by the Company with
the Securities and Exchange Commission ("SEC") on November 22, 2023.
Importantly, the record date for the stockholders
to vote at the Special Meeting remains the close of business on November 9, 2023 (the "Record Date"). Stockholders who have
previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as
of the Record Date can vote, even if they have subsequently sold their shares.
Tenon's Board of Directors recommends you
vote in support of Proposal 2. Since Proposal 2 requires an affirmative vote of a majority of the outstanding shares for passage, by not
responding with your vote you are essentially opposing this proposal. Therefore, we urge our stockholders who have not yet executed their
vote to please do so.
You may use one of the options below to ensure
that your vote is promptly recorded in time for the Special Meeting:
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company
formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using
a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal
planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the
Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest
cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on three commercial
opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, 2) Revision procedures of failed
SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. For more information, please visit https://www.tenonmed.com/.
The Tenon Medical logo, Tenon Medical and
Catamaran are registered trademarks of Tenon Medical, Inc.
Forward Looking Statements
This press release contains "forward-looking
statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates
will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates,"
"hopes," "projects," "plans," "expects," "seek," "believes," "see,"
"should," "will," "would," "target," and similar expressions and the negative versions thereof.
Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors
it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain
and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements
as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those
expressed in our forward-looking statements, please review our Annual Report on Form 10-K for the fiscal year ended December 31, 2022
on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk
Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future
events or otherwise unless required by law.
Shannon Devine / Rory Rumore